SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

US Patent Office Allows Solvonis Therapeutics’ Ketamine Patent

The company said the patent allowance covers behavioural addictions.

SVNS

Related stories